|
WO2005049593A2
(en)
*
|
2003-11-13 |
2005-06-02 |
Abbott Laboratories |
N-acylsulfonamide apoptosis promoters
|
|
US8728516B2
(en)
*
|
2009-04-30 |
2014-05-20 |
Abbvie Inc. |
Stabilized lipid formulation of apoptosis promoter
|
|
US8362013B2
(en)
|
2009-04-30 |
2013-01-29 |
Abbvie Inc. |
Salt of ABT-263 and solid-state forms thereof
|
|
ES2546294T7
(es)
*
|
2009-05-26 |
2024-06-06 |
Abbvie Ireland Unlimited Co |
Agentes inductores de la apoptosis para el tratamiento de cáncer y enfermedades inmunitarias y autoinmunitarias
|
|
US20220315555A1
(en)
|
2009-05-26 |
2022-10-06 |
Abbvie Inc. |
Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
|
|
TWI540132B
(zh)
*
|
2009-06-08 |
2016-07-01 |
亞培公司 |
Bcl-2族群抑制劑之口服醫藥劑型
|
|
TWI532484B
(zh)
*
|
2009-06-08 |
2016-05-11 |
艾伯維有限公司 |
包含凋亡促進劑之固態分散劑
|
|
KR20120085781A
(ko)
|
2009-09-20 |
2012-08-01 |
아보트 러보러터리즈 |
Bcl-2 단백질 관련 질환을 치료하는데 사용하기 위한 abt-263 결정 형태 및 용매화물
|
|
US8927009B2
(en)
*
|
2009-12-22 |
2015-01-06 |
Abbvie Inc. |
ABT-263 capsule
|
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
|
CN101798292A
(zh)
*
|
2010-03-29 |
2010-08-11 |
无锡好芳德药业有限公司 |
ABT-263衍生的新型Bcl-2蛋白抑制剂的制备
|
|
UA113500C2
(xx)
|
2010-10-29 |
2017-02-10 |
|
Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
|
|
JP2014501235A
(ja)
|
2010-12-13 |
2014-01-20 |
ノバルティス アーゲー |
二量体iap阻害剤
|
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
|
CN102584744B
(zh)
*
|
2011-01-06 |
2015-07-01 |
上海药明康德新药开发有限公司 |
4-(4-((2-(4-氯苯基)-5,5-二甲基环己基-1-烯)甲基)哌嗪-1-基)苯甲酸的合成方法
|
|
JP5898419B2
(ja)
*
|
2011-06-07 |
2016-04-06 |
公益財団法人相模中央化学研究所 |
(トリフルオロメチルスルホニル)ベンゼン誘導体の製造方法
|
|
BR112014016870A2
(pt)
|
2012-01-09 |
2017-06-27 |
Huesken Dieter |
composições orgânicas para tratar doenças relacionadas com beta-catenina
|
|
NZ710385A
(en)
|
2013-02-19 |
2016-10-28 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
MX366978B
(es)
|
2013-03-15 |
2019-08-01 |
Novartis Ag |
Conjugados de anticuerpo - farmaco.
|
|
FR3008093B1
(fr)
*
|
2013-07-04 |
2015-12-11 |
Rhodia Operations |
Procede de fluoration de composes halogenures de sulfonyle
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
|
US20170216286A1
(en)
|
2014-01-28 |
2017-08-03 |
Mayo Foundation For Medical Education And Research |
Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
|
|
US20190269675A1
(en)
|
2014-01-28 |
2019-09-05 |
Buck Institute for Research and Aging |
Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
|
|
US9993472B2
(en)
|
2014-01-28 |
2018-06-12 |
Unity Biotechnology, Inc. |
Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2
|
|
US10328058B2
(en)
|
2014-01-28 |
2019-06-25 |
Mayo Foundation For Medical Education And Research |
Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
|
|
CN106456699B
(zh)
|
2014-05-05 |
2021-07-02 |
生物风险投资有限责任公司 |
作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法
|
|
CA2955972A1
(en)
|
2014-07-22 |
2016-01-28 |
Bioventures, Llc. |
Compositions and methods for selectively depleting senescent cells
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
MX2017001946A
(es)
|
2014-08-12 |
2017-06-19 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6.
|
|
UY36401A
(es)
|
2014-11-14 |
2016-06-30 |
Novartis Ag |
Conjugados anticuerpos-fármacos
|
|
MX375970B
(es)
|
2014-12-23 |
2025-03-06 |
Novartis Ag |
Compuestos de triazolopirimidina y usos de los mismos.
|
|
EP3274344B1
(en)
|
2015-03-25 |
2019-04-24 |
Novartis Ag |
Formylated n-heterocyclic derivatives as fgfr4 inhibitors
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
WO2016203406A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
CN108348611A
(zh)
|
2015-08-28 |
2018-07-31 |
诺华股份有限公司 |
使用pi3k抑制剂和mdm2抑制剂的联合疗法
|
|
CR20180229A
(es)
|
2015-10-29 |
2018-08-24 |
Novartis Ag |
Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
|
|
WO2017160954A1
(en)
|
2016-03-15 |
2017-09-21 |
Seattle Genetics, Inc. |
Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
|
|
IL295472B2
(en)
|
2016-03-28 |
2024-10-01 |
Presage Biosciences Inc |
Pharmaceutical combinations for the treatment of cancer
|
|
CN109152933B
(zh)
|
2016-04-21 |
2022-12-02 |
生物风险投资有限责任公司 |
诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
|
|
DK3452465T3
(da)
|
2016-05-04 |
2021-02-08 |
Genoscience Pharma |
Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
|
|
PT3468972T
(pt)
|
2016-06-14 |
2020-08-21 |
Novartis Ag |
Compostos e composições para inibir a atividade da shp2
|
|
JP7042812B2
(ja)
|
2016-06-20 |
2022-03-28 |
ノバルティス アーゲー |
トリアゾロピリミジン化合物の結晶形態
|
|
JP2019524872A
(ja)
|
2016-06-20 |
2019-09-05 |
ノバルティス アーゲー |
癌の治療に有用なイミダゾピリミジン化合物
|
|
US10689378B2
(en)
|
2016-06-20 |
2020-06-23 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
JP7447002B2
(ja)
|
2017-09-11 |
2024-03-11 |
クルーゾン・ファーマシューティカルズ・インコーポレイテッド |
SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
|
|
ES3041854T3
(en)
|
2018-01-22 |
2025-11-17 |
Bioventures Llc |
Bcl-2 proteins degraders for cancer treatment
|
|
CN112437772B
(zh)
|
2018-04-29 |
2023-11-21 |
百济神州有限公司 |
Bcl-2抑制剂
|
|
WO2019221755A1
(en)
|
2018-05-18 |
2019-11-21 |
Bioventures, Llc |
Piperlongumine analogues and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
JP7337174B2
(ja)
|
2018-09-18 |
2023-09-01 |
ニカング セラピューティクス, インコーポレイテッド |
Srcホモロジー-2ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
|
|
WO2020068867A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
|
EP3856349A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
|
EP3856345A1
(en)
|
2018-09-29 |
2021-08-04 |
Novartis AG |
Process of manufacture of a compound for inhibiting the activity of shp2
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
AU2019409132B2
(en)
|
2018-12-21 |
2026-08-06 |
Novartis Ag |
Antibodies to PMEL17 and conjugates thereof
|
|
CN109851535A
(zh)
*
|
2019-01-30 |
2019-06-07 |
天津现代职业技术学院 |
一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
TW202045174A
(zh)
|
2019-02-28 |
2020-12-16 |
日商富士軟片股份有限公司 |
組合醫藥
|
|
JP2022542437A
(ja)
|
2019-08-02 |
2022-10-03 |
ランティオペプ ベスローテン ヴェンノーツハップ |
癌の処置に用いるアンジオテンシン2型(at2)受容体アゴニスト
|
|
AU2020328598B2
(en)
|
2019-08-15 |
2026-07-02 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
DK4034535T3
(da)
|
2019-09-26 |
2026-04-07 |
Novartis Ag |
Aza-quinolinforbindelser og anvendelser deraf
|
|
WO2021083135A1
(en)
|
2019-10-28 |
2021-05-06 |
Beigene, Ltd. |
Bcl-2 INHIBITORS
|
|
EP4054585A1
(en)
|
2019-11-05 |
2022-09-14 |
Abbvie Inc. |
Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
CN116969937B
(zh)
|
2020-04-15 |
2026-03-24 |
百济神州(苏州)生物科技有限公司 |
Bcl-2抑制剂
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
WO2021233948A1
(en)
|
2020-05-19 |
2021-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat a pathogen lung infection
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4175644A1
(en)
|
2020-07-06 |
2023-05-10 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
|
US20230321285A1
(en)
|
2020-08-31 |
2023-10-12 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
|
AU2021409561A1
(en)
|
2020-12-22 |
2023-07-06 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
CN117242060B
(zh)
|
2021-01-13 |
2026-07-17 |
蒙特罗莎治疗股份有限公司 |
异吲哚啉酮化合物
|
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
WO2022219412A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
|
EP4323350A1
(en)
|
2021-04-14 |
2024-02-21 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
|
AU2022258829A1
(en)
|
2021-04-16 |
2023-10-26 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023284730A1
(en)
|
2021-07-14 |
2023-01-19 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
|
JP2024528174A
(ja)
|
2021-08-02 |
2024-07-26 |
アセンテージ ファーマ(スーチョウ)カンパニー,リミティド |
医薬組合せおよびその使用
|
|
CN118660886A
(zh)
|
2021-12-09 |
2024-09-17 |
佛罗里达大学研究基金公司 |
用于治疗癌症的bcl-xl/bcl-2双重降解剂
|
|
KR20240167846A
(ko)
|
2022-03-28 |
2024-11-28 |
니캉 테라퓨틱스 인코포레이티드 |
사이클린 의존적 키나제 2 억제제로서의 설폰아미도 유도체
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CN119790053A
(zh)
|
2022-06-08 |
2025-04-08 |
霖康疗法公司 |
作为细胞周期蛋白依赖性激酶2抑制剂的磺酰胺衍生物
|
|
JP2025524064A
(ja)
|
2022-07-26 |
2025-07-25 |
ノバルティス アーゲー |
Akr1c3依存性kars阻害剤の結晶形態
|
|
IL320316A
(en)
|
2022-11-11 |
2025-06-01 |
Nikang Therapeutics Inc |
Bifunctional compounds containing pyrimidine derivatives with substitutions at positions 2 and 5, for degradation of cyclin-dependent kinase 2 (CDK2) via the ubiquitin-proteasome pathway
|
|
JPWO2024219442A1
(pl)
|
2023-04-19 |
2024-10-24 |
|
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
WO2025087879A2
(en)
|
2023-10-23 |
2025-05-01 |
Institut National de la Santé et de la Recherche Médicale |
Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
|
|
CN122249438A
(zh)
|
2023-11-27 |
2026-06-19 |
霖康疗法公司 |
用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2和细胞周期蛋白依赖性激酶4的含有2,5-取代的嘧啶衍生物的双功能化合物
|
|
CN122341597A
(zh)
|
2023-12-02 |
2026-07-03 |
霖康疗法公司 |
用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有2,5-取代的嘧啶衍生物的双功能化合物
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
CN119874465B
(zh)
*
|
2025-01-15 |
2025-12-19 |
海南大学 |
一种合成氟烷基取代4,4'-二氨基二苯甲烷类化合物的方法
|